Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2008

View Archived Issues

siRNAs targeting PCSK9 reduce cholesterol in animals

Development of cannabinoid CB1 ligands for brain imaging described

Novel dual HER1/HER2 inhibitor shows antitumor activity in vivo

Novel spirofuran potassium channel openers designed for urinary incontinence

Novel alpha7 neuronal nicotinic receptor agonists synthesized at Abbott

New agents for treating obesity and nutritional disorders presented in recent patents

GPR88 identified as a potential target in psychiatric disorders

Novel JAK-3 inhibitor active as immunosuppressant in trachea transplanted rats

Clinical benefits and safety of novel antiplatelet agent SCH-530348 disclosed at the ESC congress

GSK withdraws European MAA for Quintanrix vaccine

FDA notifies Introgen that Advexin BLA not sufficiently complete to file

FDA accepts Alpharma's Embeda capsule NDA filing

GlaxoSmithKline returns Entereg rights to Adolor for opioid bowel dysfunction

Recent Vertex patent discloses new agents for AD and other neurological disorders

Idera receives milestone payment under asthma and allergy collaboration

Recent Boehringer Ingelheim patent describes novel analgesic agents

Olanzapine long-acting injection maintains treatment benefit for up to six months

Targanta presents top-line results from oritavancin phase II SIMPLIFI trial

Roche pays USD 15 million milestone to InterMune for development of HCV protease inhibitor

Pain Therapeutics receives USD 20,000,000 in milestone payments from King Pharmaceuticals

Vimpat approved in the E.U. for partial-onset seizures

HGS reports initial top-line results from phase II HGS-ETR1 trial

Intercell reports favorable six months follow-up results from phase II HCV trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...